Dementia with Lewy bodies - a clinicopathological update.

Dementia is one of the major burdens of our aging society. According to certain predictions, the number of patients will double every 20 years. Although Alzheimer’s disease (AD), as the most frequent neurodegenerative dementia, has been extensively analysed, less is known about dementia with Lewy bodies (DLB). Neuropathological hallmarks of DLB are the deposition of intracellular Lewy bodies (LB) and Lewy neurites (LN). DLB belongs to the α-synucleinopathies, as the major component of these inclusions is pathologically aggregated α-synuclein. Depending on the localization of LBs and LNs in the central nervous system cognitive and motor symptoms can occur. In our work, we will systematically review the possible etiology and epidemiology, pathological (both macroscopic and microscopic) features, structural and functional imaging findings, with a special emphasis on the clinico-pathological correlations. Finally, we summarize the latest clinical symptoms-based diagnostic criteria and the novel therapeutic approaches. Since DLB is frequently accompanied with AD pathology, highlighting possible differential diagnostic approaches is an integral part of our paper. Although our present knowledge is insufficient, the rapid development of diagnostic and research methods provide hope for better diagnosis and more efficient treatment, contributing to a better quality of life.

[1]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[2]  C. Tanner,et al.  Bowel movement frequency in late‐life and incidental Lewy bodies , 2007, Movement disorders : official journal of the Movement Disorder Society.

[3]  I G McKeith,et al.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.

[4]  K Kosaka,et al.  Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? , 1984, Clinical neuropathology.

[5]  T. Hortobágyi,et al.  Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. , 2019, Journal of Alzheimer's disease : JAD.

[6]  J. Wiltfang,et al.  Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.

[7]  T. Hortobágyi,et al.  Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer’s disease and neocortical Lewy body disease , 2019, Scientific Reports.

[8]  Elizabeth Schroeder Activity , 2005, Encyclopedic Dictionary of Archaeology.

[9]  Clifford R Jack,et al.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.

[10]  I G McKeith,et al.  The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. , 2000, The British journal of psychiatry : the journal of mental science.

[11]  T. Hortobágyi,et al.  Depressive Symptoms in Alzheimer’s Disease and Lewy Body Dementia: A One-Year Follow-Up Study , 2011, Dementia and Geriatric Cognitive Disorders.

[12]  Dag Aarsland,et al.  Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. , 2016, Parkinsonism & related disorders.

[13]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[14]  I G McKeith,et al.  The role of levodopa in the management of dementia with Lewy bodies , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  D. Perl,et al.  Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.

[16]  G. Glover,et al.  Altered cortical visual processing in PD with hallucinations , 2004, Neurology.

[17]  K. Jellinger,et al.  Post-mortem assessment in vascular dementia: advances and aspirations , 2016, BMC Medicine.

[18]  W. M. van der Flier,et al.  The use of EEG in the diagnosis of dementia with Lewy bodies , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  R. Melis,et al.  Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders , 2009, Alzheimer's & Dementia.

[20]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[21]  T. Hortobágyi,et al.  Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.

[22]  T Ota,et al.  Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET , 2009, Neurology.

[23]  S. Pal,et al.  The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis. , 2013, Parkinsonism & related disorders.

[24]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[25]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  T. Tokuda,et al.  CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease , 2009, Brain Research.

[27]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[28]  B. Ghetti,et al.  Early‐onset Dementia with Lewy Bodies , 2004, Brain pathology.

[29]  T. Hortobágyi,et al.  Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach , 2018, Brain : a journal of neurology.

[30]  W. Hill,et al.  Contribution of somal Lewy bodies to neuronal death , 1997, Brain Research.

[31]  Hitoshi Takahashi,et al.  The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[32]  T. Hortobágyi,et al.  Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia , 2016, Alzheimer's & Dementia.

[33]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[34]  K. Jellinger,et al.  Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? , 2018, BMC Medicine.

[35]  G. Plazzi,et al.  A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. , 2011, Sleep medicine.

[36]  T. Hortobágyi,et al.  Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study , 2016, BMJ Open.

[37]  H. Mori,et al.  Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. , 1994, Biochemical and biophysical research communications.

[38]  Francesca Clerici,et al.  Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. , 2014, Journal of Alzheimer's disease : JAD.

[39]  T. Hortobágyi,et al.  Early and Presenting Symptoms of Dementia with Lewy Bodies , 2011, Dementia and Geriatric Cognitive Disorders.

[40]  Barbara B. Levin on a Longitudinal Case Study , 2001 .

[41]  Paul M. Thompson,et al.  Hippocampal shape differences in dementia with Lewy bodies , 2008, NeuroImage.

[42]  F. Lewy Paralysis agitans. I. Pathologische Anatomie , 1912 .

[43]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  K. Kosaka,et al.  Diffuse lewy body disease in Japan , 1990, Journal of Neurology.

[45]  Alan J. Thomas,et al.  Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment , 2014, Neurobiology of Aging.

[46]  C. Tanner,et al.  Association of olfactory dysfunction with incidental Lewy bodies , 2006, Movement disorders : official journal of the Movement Disorder Society.

[47]  T. Hortobágyi,et al.  Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. , 2016, Brain : a journal of neurology.

[48]  B. Boeve,et al.  Lewy body dementias , 2015, The Lancet.

[49]  V. Lee,et al.  Modeling Lewy pathology propagation in Parkinson's disease. , 2014, Parkinsonism & related disorders.

[50]  B. Dubois,et al.  Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. , 1995, Human molecular genetics.

[51]  Dag Aarsland,et al.  Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.

[52]  M. Britton,et al.  A One-Year Follow-up Study , 2005 .

[53]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[54]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[55]  Dag Aarsland,et al.  Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration , 2019, Acta neuropathologica communications.

[56]  T. Hortobágyi,et al.  Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer’s Disease , 2020, Brain sciences.

[57]  K. Davis,et al.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.

[58]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[59]  T. Hortobágyi,et al.  Unfolded protein response is activated in Lewy body dementias , 2016, Neuropathology and applied neurobiology.

[60]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[61]  K. Heilman,et al.  Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank , 2002, Alzheimer disease and associated disorders.

[62]  J. Morris,et al.  Greenfield's Neuropathology Edited by J. Hume-Adams and L. W. Ducken. Fifth edition. Oxford University Press, New York (1992), 1557pp. Price £145, U.S.$195 , 1993, Neuroscience.

[63]  D. V. von Cramon,et al.  In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[64]  T. Hortobágyi,et al.  Behavioural and Psychological Symptoms in Neurocognitive Disorders: Specific Patterns in Dementia Subtypes , 2019, Open medicine.

[65]  D. Dickson,et al.  Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.

[66]  J Q Trojanowski,et al.  Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. , 1991, The American journal of pathology.

[67]  T. Hortobágyi,et al.  Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration , 2018, Molecular Brain.

[68]  B. Boeve,et al.  REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.

[69]  J. Wiltfang,et al.  Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. , 2005, Dementia and geriatric cognitive disorders.

[70]  B. Mollenhauer,et al.  Biomarkers in biological fluids for dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.

[71]  L. Ferini-Strambi,et al.  REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders. , 2014, Archives italiennes de biologie.

[72]  Alan J. Thomas,et al.  Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia , 2017, Journal of Alzheimer's disease : JAD.

[73]  D. Maraganore,et al.  Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? , 2011, Neurobiology of Aging.

[74]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[75]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Price,et al.  Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease , 2011, Neurology.

[77]  Eric E. Smith,et al.  The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[78]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[79]  D. Dickson,et al.  Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? , 2005, Parkinsonism & related disorders.

[80]  A. Chincarini,et al.  Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies , 2019, Movement disorders : official journal of the Movement Disorder Society.

[81]  J. O'Brien,et al.  Magnetic Resonance Imaging in Lewy Body Dementias , 2009, Dementia and Geriatric Cognitive Disorders.

[82]  Alan J. Thomas,et al.  Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia , 2014, F1000Research.

[83]  K. Jellinger,et al.  Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease , 2002, Journal of Neural Transmission.

[84]  B. Boeve,et al.  Sleep in Parkinson’s Disease and Dementia with Lewy Bodies , 2012 .

[85]  Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[86]  Tetsuya Mori,et al.  Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies , 2004, Annals of nuclear medicine.

[87]  T. Bird,et al.  Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families. , 2002, Archives of neurology.

[88]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[89]  T. Hortobágyi,et al.  Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. , 2017, Journal of Alzheimer's disease : JAD.

[90]  L. Thal,et al.  Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.

[91]  S Noachtar,et al.  Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. , 2000, Brain : a journal of neurology.

[92]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[93]  D. Galasko,et al.  Reduced hypocretin (orexin) levels in dementia with Lewy bodies , 2010, Neuroreport.

[94]  Ronald C Petersen,et al.  Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. , 2011, Sleep medicine.

[95]  K. Ishii,et al.  Regional cerebral blood flow difference between dementia with Lewy bodies and AD , 1999, Neurology.

[96]  W. Schulz-Schaeffer The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[97]  P. Scheltens,et al.  The significance of medial temporal lobe atrophy , 2007, Neurology.

[98]  John-Paul Taylor,et al.  Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies , 2015, Neurobiology of Aging.

[99]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[100]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[101]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[102]  S. Gabriel,et al.  Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.

[103]  H. Braak,et al.  Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease , 2010, Acta Neuropathologica.

[104]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[105]  E. Sinforiani,et al.  Analysis of video‐polysomnographic sleep findings in dementia with Lewy bodies , 2013, Movement disorders : official journal of the Movement Disorder Society.

[106]  O. Hoffmann,et al.  Amyloid β Peptide and Precursor Protein (APP) in Mild and Severe Brain Ischemia , 1997 .

[107]  F. Lebert,et al.  [Treatment of dementia with Lewy bodies]. , 2006, Revue neurologique.

[108]  Dag Aarsland,et al.  Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies , 2007, Neurology.

[109]  B. Mollenhauer,et al.  Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies , 2016, Journal of Neurology.

[110]  F. Hirth,et al.  Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease , 2018, Front. Neurosci..

[111]  E. Kuusisto,et al.  Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α‐Synuclein, Ubiquitin, and p62 , 2003, Journal of neuropathology and experimental neurology.

[112]  T. Montine,et al.  RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient , 2008, Brain pathology.

[113]  M. David,et al.  Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis , 2016, PloS one.

[114]  D. Aarsland,et al.  Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure , 2019, European Geriatric Medicine.

[115]  I. McKeith,et al.  Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[116]  Alan J. Thomas,et al.  Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. , 2015, The American journal of psychiatry.

[117]  Andrew King,et al.  Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.

[118]  G Halliday,et al.  pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium , 2009, Neuropathology and applied neurobiology.

[119]  Robert Howard,et al.  Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. , 2006, Brain : a journal of neurology.

[120]  Ludwig Kappos,et al.  Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.

[121]  B S Linn,et al.  The Rapid Disability Rating Scale—2 , 1982, Journal of the American Geriatrics Society.

[122]  Introduction to Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders , 2011 .

[123]  E. Tolosa,et al.  Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.

[124]  B. Mollenhauer,et al.  The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. , 2016, Biomarkers in medicine.

[125]  Guy B. Williams,et al.  Neuroimaging characteristics of dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.

[126]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[127]  D. Aarsland,et al.  ( 123 I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study , 2013 .

[128]  John O'Brien,et al.  Neuroimaging of dementia with Lewy bodies. , 2012, Neuroimaging clinics of North America.

[129]  Alan J. Thomas,et al.  Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. , 2015, Journal of Alzheimer's disease : JAD.

[130]  I. McKeith Commentary: DLB and PDD: the same or different? Is there a debate? , 2009, International Psychogeriatrics.

[131]  T. Hortobágyi,et al.  Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features , 2011, International journal of geriatric psychiatry.

[132]  W. F. Abdo,et al.  CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.

[133]  Eka Swadiansa The hypothesis , 1990 .

[134]  Dag Aarsland,et al.  Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.

[135]  A. Kakita,et al.  Relationship Among &agr;-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra , 2006, Journal of neuropathology and experimental neurology.

[136]  H. Braak,et al.  Staging of Sporadic Parkinson Disease-Related α-Synuclein Pathology: Inter- and Intra-Rater Reliability , 2005, Journal of neuropathology and experimental neurology.

[137]  I. McKeith,et al.  High prevalence of neurovascular instability in neurodegenerative dementias , 1998, Neurology.

[138]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[139]  J. Kessler,et al.  Task force WANTED: many reasons to promote research on cognitive rehabilitation to prevent, delay, and treat cognitive dysfunctions in patients with Parkinson's disease. , 2015, Parkinsonism & related disorders.